Exicure (XCUR) Non-Current Deferred Tax Liability (2025 - 2026)

Exicure (XCUR) reported Non-Current Deferred Tax Liability of $423000.0 for Q1 2026, little changed quarter-over-quarter from $423000.0 in Q4 2025.

Exicure (XCUR) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends

Exicure has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $423000.0 in Q1 2026.

For the quarter ending Q1 2026, Non-Current Deferred Tax Liability changed N/A year-over-year to $423000.0; the trailing twelve-month figure through Mar 2026 stood at $423000.0 (changed N/A YoY), and the FY2025 full-year result was $423000.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability for Q1 2026 stood at $423000.0, roughly flat from $423000.0 in the prior quarter.
The five-year high for Non-Current Deferred Tax Liability was $423000.0 in Q4 2025, with the low at $423000.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	719,706.53 Bn	719,706.50 Bn	-
2	Belite Bio	55,800.00 Bn	55,800.00 Bn	-
3	Quantum Biopharma	18,182.30 Bn	18,182.29 Bn	-
4	Legend Biotech	3,154.00 Bn	3,153.71 Bn	242.10 Mn
5	Akari Therapeutics	1,844.30 Bn	1,844.29 Bn	-
6	Evaxion A	1,567.96 Bn	1,567.94 Bn	-
7	Psyence Biomedical	251.43 Bn	251.42 Bn	-
8	Vertex Pharmaceuticals	112.56 Bn	105.31 Bn	2.59 Bn
9	Abivax	94.37 Bn	94.37 Bn	-
10	Exicure	19.38 Mn	16.77 Mn	-

Download Data